# Golidocitinib

Source: https://onco.cc/drugs/golidocitinib/  
OnCo record `golidocitinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.

## Summary

Dizal Pharmaceutical's golidocitinib (DZD4205) was approved by the NMPA in June 2024 for relapsed or refractory peripheral T-cell lymphoma, on the JACKPOT8 trial in which about 44 percent of patients responded. It is the first JAK1-selective inhibitor approved for a cancer. A phase 3 trial testing it as maintenance after first-line therapy is registered.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: DZD4205
- Modality: Oral selective JAK1 inhibitor
- Mechanism: Selectively inhibits Janus kinase 1, the signalling node that peripheral T-cell lymphoma cells use through the JAK-STAT pathway.
- Approvals: CN 2024: Relapsed or refractory peripheral T-cell lymphoma

## Sources

- ClinicalTrials.gov: trials of Golidocitinib: https://clinicaltrials.gov/search?intr=DZD4205

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- trials: [A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)](https://onco.cc/trials/nct07234162/), [Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)](https://onco.cc/trials/nct07496229/)

---
JSON: https://onco.cc/api/v1/entities/golidocitinib.json